Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 55.1% in July

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,050,000 shares, an increase of 55.1% from the June 30th total of 677,100 shares. Approximately 3.5% of the shares of the company are sold short. Based on an average daily volume of 313,000 shares, the short-interest ratio is currently 3.4 days.

Werewolf Therapeutics Stock Performance

HOWL traded down $0.01 on Friday, hitting $2.73. The company’s stock had a trading volume of 166,103 shares, compared to its average volume of 475,917. The company’s 50 day simple moving average is $3.24 and its 200-day simple moving average is $4.93. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19. The firm has a market cap of $118.65 million, a P/E ratio of -2.50 and a beta of 0.46.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Analysts forecast that Werewolf Therapeutics will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HOWL. Financial Perspectives Inc boosted its stake in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after buying an additional 3,000 shares during the period. Certuity LLC purchased a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at about $39,000. Lighthouse Investment Partners LLC bought a new stake in shares of Werewolf Therapeutics during the 4th quarter valued at about $87,000. Denali Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the first quarter worth about $172,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $165,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on HOWL shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday, June 26th. Finally, Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Werewolf Therapeutics in a research note on Monday, June 3rd.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.